Leerink initiated coverage of Adlai Nortye (ANL) with an Outperform rating and $23 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANL:
- Adlai Nortye files to sell $600M of Class A ordinary shares
- Adlai Nortye files to sell 64.62M Class A ordinary shares for holders
- Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic
- Adlai Nortye upgraded to Buy from Neutral at H.C. Wainwright
- Adlai Nortye Doses First Patient in Global Phase 1 Trial of Pan-RAS Inhibitor AN9025